Ge Healthcare Limited

Ge Healthcare As

Anormed, Inc.

Nigel Anthony Powell

Harry John Wadsworth

Anthony Eamon Storey

Dimitrios Mantzilas

Steven Michael Fairway

Eric Horn

Philip Duncanson

Alan Cuthbertson

Robert A Snow

Gregory L McIntire

Magne Solbakken

Barry A Murrer

Evan E Gustow

Dagfinn Lovhaug

Roger Paul Pettitt

Brian Higley

Dewi M Lewis

Lucinda A Dollimore

Barry Anthony Murrer

The present invention provides an automated method for the preparation ofI-labelled radiopharmaceutical compositions, together with disposable cassettes for use in the method. The use of an automated synthesizer apparatus in the preparation ofI-labelled radiopharmaceuticals is also described. Also described is the use of cassettes of the present invention in the preparation ofI-labelled radiopharmaceuticals.

Automated radiolabelling method

A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Flutemetamol (F) Injection for the imaging of &#x3b2;-amyloid plaques in the brain and methods and devices for preparing same are described including the automated synthesis and purification of [F]flutemetamol by means of solid phase extraction (SPE).

Purification method

A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Flutemetamol (18F) Injection for the imaging of b amyloid plaques in the brain and methods and devices for preparing same are described including the automated synthesis and purification of [18F]flutemetamol by means of solid phase extraction (SPE).

The present invention provides tetra-amine chelator conjugates with biological targeting moieties, linked via a linker group and technetium complexes thereof as radiopharmaceuticals. The linker group is such that the chelator is mono-functionalized at the bridgehead position and provides both flexibility and a lack or aryl groups, to minimize lipophilicity and steric hulk. Protected versions of the chelators are provided which permit conjugation with a wide range of targeting molecules without interfering reactions with the amine nitrogens of the tetra-amine chelator. Syntheses of the functionalised chelators are described, together with bifunctional chelate precursors. Radiopharmaceutical compositions comprising the technetium metal complexes of the invention are described, together with non-radioactive kits for the preparation of such radiopharmaceuticals.

N4 chelator conjugates

A contrast agent of formula I: V-L-R (I) where V is an organic group having binding affinity for an angiotensin II receptor site, L is a linear or branched amino acid-comprising biomodifier or linker moiety, and R is a reporter moiety detectable in in vivo imaging of a human or animal body.

Contrast agent

The invention provides the use of a radiation source which is a low energy X-ray emitter, e.g. with an energy of emission of the principal photon in the range of 20 to 100 keV, preferably 20 to 40 keV and with a half life of 10 to 100 days, preferably 15 to 70 days, for the treatment of restenosis. Suitable radioisotopes include palladium-103, dysprosium-159, samarium-145, cadmium-109, ytterbium-169 and preferably iodine-125. High activity radioactive bodies and sources comprising such radioisotopes, and methods for the manufacture of such sources, are also disclosed.

Apparatus and methods for radiotherapy

Pharmaceutical composition containing selected lanthanum carbonate

Growing community of inventors

Buckinghamshire, United Kingdom

Nigel Anthony Powell